Hercules, CA — April 2, 2014 — Bio-Rad Laboratories, Inc. today announced the launch of its Precision Blue real-time PCR dye, making it easier for researchers to set up real-time PCR (qPCR) experiments.
The blue dye improves the visibility of qPCR reaction mixtures, enabling loading of small volume reactions with greater speed, accuracy, and precision. Applications such as single nucleotide polymorphism (SNP) genotyping and high-throughput gene expression analysis using 384-well plates will particularly benefit from use of this dye.
Precision Blue dye is compatible with Bio-Rad’s universal qPCR supermixes ( iTaq™ universal and SsoAdvanced™ universal supermixes) and does not interfere with SYBR® Green- or probe-based detection. The dye can be used with all Bio-Rad CFX real-time PCR systems and all other vendors’ real-time PCR systems.
For convenience, Precision Blue can be added directly to the supermix or used as a component of a reaction master mix. The dye is concentrated 200x, and delivers 500 x 20 µl reactions.
For more information about Precision Blue dye, please visit www.bio-rad.com/PrecisionBlue.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) designs, manufactures, and distributes a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs approximately 7,750 people worldwide and had revenues exceeding $2 billion in 2013. For more information, visit our website at www.bio rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
Paul Streng
Bio-Rad Laboratories, Inc.
510-741-6210
Paul_Streng@bio-rad.com
Ken Li
Chempetitive Group
312-997-2436 x 112
kli@chempetitive.com